8 results about "Αvβ3 integrin" patented technology

This patent discloses a dual targeting lipid-based formulation designed for precise drug delivery to the thyroid gland, addressing the complexities of thyroid disorders. The formulation integrates two key technologies: the RGDFK Targeting Motif and Iodine Coupling. The RGDFK motif enhances specific binding to αvβ3 integrin receptors, facilitating internalization of therapeutic agents. Simultaneously, the Iodine Coupling technology leverages the thyroid gland's natural affinity for iodine, ensuring increased accumulation of lipid-based vesicles in thyroid tissue. Applications of this formulation extend to targeted treatment of diverse thyroid disorders, symptom-specific relief, and nutritional supplementation. The formulation serves as a fundamental component in pharmaceutical compositions, adaptable for various administration routes. The manufacturing process emphasizes scalability, reproducibility, and standardized quality. A comprehensive treatment kit has been devised, offering a convenient and tailored approach to thyroid drug delivery. In conclusion, this dual targeting lipid-based formulation signifies a paradigm shift in thyroid disorder therapeutics, promising precision, efficacy, and patient-centric care. As it advances towards clinical applications, it holds the potential to redefine the landscape of thyroid health management for enhanced patient outcomes.

The invention relates to a polypeptide, a preparation method and application thereof, and a drug for treating head and neck cancer, the polypeptide is an iRGD-TRP-PK1 fusion peptide, and comprises an iRGD targeting peptide sequence and a TRP-PK1 sequence; the iRGD-TRP-PK1 fusion peptide can specifically target an alpha v beta 3 integrin highly expressed on the surface of a tumor cell, and induces death of the tumor cell through a potassium leakage channel formed by TRP-PK1. The polypeptide provided by the invention can be combined with head and neck cancer cells with high expression of integrin alphaVbeta3, so that the operation complexity of a targeted delivery system is effectively reduced, the stability is improved, and a new treatment strategy and application prospect are provided for tumor treatment.

Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and / or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.

The invention discloses a tumor targeted diagnosis and treatment integrated system based on organic-inorganic dynamic assembly and a preparation method thereof, the system takes an aminated mesoporous nano-material as a carrier to load a chemotherapeutic drug and a photothermal agent, and realizes alpha v beta 3 integrin targeting through RGD peptide modification. And furthermore, sodium alginate (Alg-NB) grafted with N-(2-aminoethyl)-4-(4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy) methyl butyrate (NB) with pH / NIR dual response is utilized, and through Schiff base reaction and calcium ion crosslinking coating, an intelligent nano diagnosis and treatment platform is formed. According to the invention, a'dynamic gating 'release mechanism is created for the first time, and time-space controllable drug release is realized. By integrating a photo-thermal / photodynamic, chemotherapy and active targeting triple synergistic treatment mode, an efficient anti-tumor effect is achieved. In addition, the system achieves the diagnosis and treatment integrated function in a breakthrough mode, has the near-infrared fluorescence imaging and thermal imaging guiding capacity, and provides support for precise treatment in an operation. The invention provides a new idea for a new generation of organic-inorganic dynamically assembled targeted integrated diagnosis and treatment system.

The invention discloses a linker compound of an integrin alpha v beta 3 inhibitor, which is shown as a formula (1) and can be used for a prodrug delivery system, or a tautomer, a mesomer, a raceme, an enantiomer, a diastereoisomer of the linker compound, or a mixture form of the linker compound, or a pharmaceutically acceptable salt, a prodrug or a solvate of the linker compound, and a synthesis method and application of the linker compound. The structure of the formula (1) comprises an alpha v beta 3 integrin antagonist, a connecting unit, a polyethylene glycol (PEG) spacer and a cytotoxic element. IA-LI-PD (1).

Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and / or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.

The present invention provides a neutrophil biomimetic vesicle nanoformulation, a preparation method thereof, and an application in the preparation of gastric cancer targeted drugs, belonging to the field of biopharmaceutical technology. The present invention uses RGD cyclic peptide to modify neutrophil biomimetic vesicles. RGD cyclic peptide is a tumor-targeting peptide that can bind to αvβ3 receptors and is a highly efficient and selective inhibitor of αvβ3 integrin receptors. The neutrophil biomimetic vesicles modified with RGD cyclic peptide have good gastric cancer cell targeting. The present invention uses neutrophil biomimetic vesicles modified with RGD cyclic peptide to wrap drug-loaded photosensitive liposomes. The drug-loaded photosensitive liposomes contain photosensitizers. The photosensitizers have photothermal corresponding properties. Under near-infrared zone II laser irradiation, the photothermal effect of the photosensitizer causes the drug-loaded photosensitive liposomes to decompose, releasing the active ingredients PD-L1 inhibitor and doxorubicin, thereby inhibiting the proliferation of gastric cancer cells, delaying the occurrence and development of gastric cancer, and achieving the effect of targeted treatment of gastric cancer.

Disclosed are an αvβ3 integrin targeting single-domain antibody and various applications thereof. The αvβ3 integrin targeting single-domain antibody exhibits high binding ability to αvβ3 integrin related to angiogenesis, excellent tissue permeability, and biostability compared to conventional antibodies. Further, the single-domain antibody may be combined with fluorescent particles and thus may be easily measured in vitro, in vivo or ex vivo, and may be effective in detecting angiogenesis and diagnosing angiogenesis related diseases, therefore it may be usefully used in related industries.